BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...focused on collagenase-based therapies, hired Kevin Buchi as CEO. Buchi was president and CEO of TetraLogic Pharmaceuticals Corp....
BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...Therapeutics Inc., Syros Pharmaceuticals Inc., Tensha Therapeutics Inc. -- now part of Roche -- and TetraLogic Pharmaceuticals Corp....
BioCentury | Jun 22, 2018
Clinical News

Medivir delays remetinostat Phase III

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp....
BioCentury | Jun 18, 2018
Clinical News

Medivir delays remetinostat Phase III

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp. Alicia...
BioCentury | Nov 28, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on GDF1, MYH6 and FLT4 could help predict the risk of subtypes of congenital heart disease. Whole-exome sequencing of 2,871 congenital heart disease patients identified associations between severe disease in the Ashkenazi...
BioCentury | May 1, 2017
Company News

BioCurate names Begley CEO

...most recently CSO of Akriveia Therapeutics LLC (Thousand Oaks, Calif.), and was previously CSO at TetraLogic Pharmaceuticals Corp....
...to bridge the gap and consolidate the region's biotech investment expertise. Mark Zipkin Akriveia Therapeutics LLC Amgen Inc. Monash University TetraLogic Pharmaceuticals Corp. University...
BioCentury | Apr 12, 2017
Clinical News

Remetinostat: Additional Ph II data

...remetinostat dose. Last year, Medivir acquired remetinostat from TetraLogic Pharmaceuticals Corp. (see BioCentury, Nov. 3, 2016 ). TetraLogic...
BioCentury | Apr 7, 2017
Clinical News

Medivir CTCL candidate headed for Phase III

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp....
BioCentury | Nov 18, 2016
Company News

Management tracks

...Akriveia Therapeutics LLC (Thousand Oaks, Calif.) named C. Glenn Begley CSO. He was CSO at TetraLogic Pharmaceuticals Corp....
BioCentury | Nov 3, 2016
Company News

TetraLogic, Medivir deal

...cash; TetraLogic will subsequently delist from NASDAQ and terminate all remaining employees by Dec. 1. TetraLogic...
...in regulatory milestones and $31 million in commercialization milestones, plus tiered royalties capped at 13%. TetraLogic...
...close this year, contingent on the approval of TetraLogic’s shareholders (see BioCentury, Feb. 1 ). TetraLogic Pharmaceuticals Corp....
Items per page:
1 - 10 of 60
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...focused on collagenase-based therapies, hired Kevin Buchi as CEO. Buchi was president and CEO of TetraLogic Pharmaceuticals Corp....
BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...Therapeutics Inc., Syros Pharmaceuticals Inc., Tensha Therapeutics Inc. -- now part of Roche -- and TetraLogic Pharmaceuticals Corp....
BioCentury | Jun 22, 2018
Clinical News

Medivir delays remetinostat Phase III

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp....
BioCentury | Jun 18, 2018
Clinical News

Medivir delays remetinostat Phase III

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp. Alicia...
BioCentury | Nov 28, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on GDF1, MYH6 and FLT4 could help predict the risk of subtypes of congenital heart disease. Whole-exome sequencing of 2,871 congenital heart disease patients identified associations between severe disease in the Ashkenazi...
BioCentury | May 1, 2017
Company News

BioCurate names Begley CEO

...most recently CSO of Akriveia Therapeutics LLC (Thousand Oaks, Calif.), and was previously CSO at TetraLogic Pharmaceuticals Corp....
...to bridge the gap and consolidate the region's biotech investment expertise. Mark Zipkin Akriveia Therapeutics LLC Amgen Inc. Monash University TetraLogic Pharmaceuticals Corp. University...
BioCentury | Apr 12, 2017
Clinical News

Remetinostat: Additional Ph II data

...remetinostat dose. Last year, Medivir acquired remetinostat from TetraLogic Pharmaceuticals Corp. (see BioCentury, Nov. 3, 2016 ). TetraLogic...
BioCentury | Apr 7, 2017
Clinical News

Medivir CTCL candidate headed for Phase III

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp....
BioCentury | Nov 18, 2016
Company News

Management tracks

...Akriveia Therapeutics LLC (Thousand Oaks, Calif.) named C. Glenn Begley CSO. He was CSO at TetraLogic Pharmaceuticals Corp....
BioCentury | Nov 3, 2016
Company News

TetraLogic, Medivir deal

...cash; TetraLogic will subsequently delist from NASDAQ and terminate all remaining employees by Dec. 1. TetraLogic...
...in regulatory milestones and $31 million in commercialization milestones, plus tiered royalties capped at 13%. TetraLogic...
...close this year, contingent on the approval of TetraLogic’s shareholders (see BioCentury, Feb. 1 ). TetraLogic Pharmaceuticals Corp....
Items per page:
1 - 10 of 60